Palbociclib in combination with anastrozole or exemestane for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany. Interim results of the INGE-B phase 2 trial. 13. Dezember 2019 M. Welslau, N. Marschner, U. Söling, C. Brucker, O.J. Stoetzer, J. Meiler, P.Wimberger, S.Dörfel, J.Sahlmann, L.Houet, C.Vannier, K.Potthoff, 2019. Cancer Res February 15 2020 (80) (4 Supplement) P5-11-14 Therapy of advanced breast cancer for patients with hormone receptor-positive / HER2-negative and HER2-positive tumors is changing real life. First results from the prospective, national research platform OPAL for patients with advanced breast cancer in Germany. E. Stickeler, N. Harbeck, M. Thill, A. Nusch, M. Chiabudini, L. Kruggel, M. Jänicke, N. Marschner, M. Zahn, A. Welt, A. Wöckel, T. Decker, OPAL… Weiterlesen Palbociclib plus fulvestrant as first-line therapy for patients with locally advanced, inoperable or metastatic HR+/HER2- breast cancer in Germany: Interim results of the INGE-B phase 2 study. Welt, A., Welslau, M., Lüftner, D., Deryal, M., Liersch, R., Sahlmann, J., Houet, L., Potthoff, K., Marschner, N., 2020. Oncol Res Treat 43 (suppl 1)(270),… Weiterlesen